(VIANEWS) – SPBK1 NORD-NORGE (NONG.OL), NAVAMEDIC (NAVA.OL), ABN AMRO BANK N.V. (ABN.AS) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPBK1 NORD-NORGE (NONG.OL)
30.3% sales growth and 13.71% return on equity
SpareBank 1 Nord-Norge provides banking services in Northern Norway. It operates through Retail Market, Corporate Market, Leasing, and Markets segments. The company offers mortgage, car, vehicle, and other loan related services. It also offers vehicle, home, travel, personal, and pet insurance services. In addition, the company provides various savings and pension related services, as well as debit and credit card services. Further, it offers financing, real estate leasing, agency, payment, and investment services. The company was founded in 1836 and is headquartered in Tromsø, Norway.
Earnings Per Share
As for profitability, SPBK1 NORD-NORGE has a trailing twelve months EPS of kr9.37.
PE Ratio
SPBK1 NORD-NORGE has a trailing twelve months price to earnings ratio of 10.41. Meaning, the purchaser of the share is investing kr10.41 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.71%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Mar 31, 2023, the estimated forward annual dividend rate is 8.2 and the estimated forward annual dividend yield is 8.52%.
More news about SPBK1 NORD-NORGE.
2. NAVAMEDIC (NAVA.OL)
21.8% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.75.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 22.46. Meaning, the purchaser of the share is investing kr22.46 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr39.30 at 02:20 EST, under its 52-week high of kr43.60 and way higher than its 52-week low of kr26.00.
More news about NAVAMEDIC.
3. ABN AMRO BANK N.V. (ABN.AS)
19.6% sales growth and 9.3% return on equity
ABN AMRO Bank N.V. provides various banking products and services to retail, private, and business clients in the Netherlands and internationally. It operates through three segments: Personal & Business Banking, Wealth Management, and Corporate Banking. The company provides savings and deposits products; labelled residential mortgage products under the Florius brands; and consumer loans under the Alpha Credit Nederland, Credivance, Defam, Moneyou, and ABN AMRO brands. It also issues, promotes, manages, and processes credit cards; provides revolving credit card facilities and pension schemes, as well as consumer credit and mortgages; and life and non-life insurance products. In addition, it offers asset-based solutions, including working capital solutions, equipment leases and loans, and vendor lease services; private banking and wealth-management-related services; and derivatives and equity clearing services. ABN AMRO Bank N.V. was incorporated in 2009 and is headquartered in Amsterdam, the Netherlands.
Earnings Per Share
As for profitability, ABN AMRO BANK N.V. has a trailing twelve months EPS of €2.21.
PE Ratio
ABN AMRO BANK N.V. has a trailing twelve months price to earnings ratio of 6.6. Meaning, the purchaser of the share is investing €6.6 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.3%.
More news about ABN AMRO BANK N.V..
4. PERNOD RICARD (RI.PA)
7.9% sales growth and 14.84% return on equity
Pernod Ricard SA produces and sells wines and spirits worldwide. The company offers whiskey, vodka, gin, rum, liqueur and bitters, champagne, tequila and mezcal, and aperitif under the brands 100 Pipers, Aberlour, Absolut, Absolut Elyx, Altos, ARARAT, Augier, Avion, Ballantine's, Becherovka, Beefeater, Blenders Pride, Brancott Estate, Campo Viejo, Ceder's, Chivas, Church Road, Clan Campbell, Del Maguey, George Wyndham, Green Spot, Havana Club, Imperial, Imperial Blue, Italicus, J.P. Wiser's, Jacob's Creek, Jameson, Jefferson's, Kahlúa, Kenwood, KI NO BI, Lillet, Long John, L'Orbe, Lot No. 40, Malfy, Malibu, Martell, Method & Madness, Midleton Very Rare, Minttu, Monkey 47, Mumm, Olmeca, Ostoya, Passport Scotch, Pastis 51, Pernod, Perrier-Jouët, Plymouth Gin, Powers, Rabbit Hole, Ramazzotti, Redbreast, Ricard, Royal Salute, Royal Stag, Scapa, Seagram's Gin, Secret Speyside, Smooth Ambler, Something Special, St Hugo, Stoneleigh, Suze, The Glenlivet, TX, Wyborowa, and Ysios. It also provides non-alcoholic beverages under the brands Ceder's, Suze Tonic 0%, Cinzano Spritz 0%, Pacific, Campo Viejo Sparkling 0%, and Jacob's Creek Unvined. The company was founded in 1805 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, PERNOD RICARD has a trailing twelve months EPS of €9.33.
PE Ratio
PERNOD RICARD has a trailing twelve months price to earnings ratio of 21.64. Meaning, the purchaser of the share is investing €21.64 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.84%.
Volume
Today’s last reported volume for PERNOD RICARD is 95884 which is 76.42% below its average volume of 406750.
Revenue Growth
Year-on-year quarterly revenue growth grew by 19.4%, now sitting on 11.86B for the twelve trailing months.
Moving Average
PERNOD RICARD’s value is below its 50-day moving average of €207.81 and above its 200-day moving average of €194.56.
Sales Growth
PERNOD RICARD’s sales growth is 7.9% for the present quarter and 7.9% for the next.
More news about PERNOD RICARD.
